Drugs / Ropanicant
Ropanicant
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03551288 | May → Jul 2018 | major depressive disorder | Suven Life Sciences Limited | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06836063 | Jul 2025 → Feb 2026 | major depressive disorder | Suven Life Sciences Limited | Completed | No outcome recorded |
| Phase 2 | NCT06126497 | Feb → Jul 2024 | major depressive disorder | Suven Life Sciences Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03155503 Comparator | May 2017 → Mar 2018 | major depressive disorder | Suven Life Sciences Limited | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ropanicant | “Pharmacokinetics of Ropanicant (SUVN-911)” PMID 35963959 ↗ Aug 2022 |
| Known as | Ropanicant hydrochloride | “Ropanicant hydrochloride (previously known as SUVN-911, hereinafter referred to as ropanicant) is a novel alpha4 beta2 nicotinic acetylcholine receptor (α4β2 nAchR) antagonist...” PMID 35963959 ↗ Aug 2022 |
| Known as | SUVN-911 | “Pharmacokinetics of Ropanicant (SUVN-911)” PMID 35963959 ↗ Aug 2022 |
| Known as | SUVN-911 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650579 ↗ |
| Action | Inhibit | “is a novel alpha4 beta2 nicotinic acetylcholine receptor (α4β2 nAchR) antagonist” PMID 35963959 ↗ Aug 2022 |
| Modality | Small molecule | — CHEMBL4650579 ↗ |
| Route | Oral | “administered orally for 14 days” PMID 35963959 ↗ Aug 2022 |